The final analysis of survival data from the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is encouraging. Researchers confirmed what was seen as a trend in their initial secondary analysis: postmenopausal women with metastatic, hormone-positive breast cancer lived longer when given twice the past standard amount of fulvestrant (Faslodex).

Women 65 and older received the same treatment benefit from the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and docetaxel (Taxotere) as women 64 and younger, a sub-analysis of CLEOPATRA trial data reveals.

Women with lymphedema — swelling in the arm caused by the surgical removal of lymph nodes or by damage to the lymph nodes from radiation therapy for breast cancer — may perform upper-body strength training exercises with light and heavy weights, without worsening swelling or other lymphedema symptoms, Australian researchers say.

A study published in Psycho-Oncology suggests that the way a couple communicates about cancer-related concerns plays a role in worsening or improving symptoms of depression related to problems with sex and physical intimacy in women living with metastatic disease.

Women with HER2 positive metastatic breast cancer whose cancer grows despite other standard therapies have a new treatment option available next month, now that the Food and Drug Administration approved the EMILIA study’s T-DM1.

NEW YORK (Reuters Health) - More young women are being diagnosed with advanced, metastatic breast cancer than were three decades ago, a new study suggests - although the overall rate of cancers in that group is still small.